Medical products including modified extracellular matrix materials
View Patent ↗Described, in certain aspects, are medical products comprised of uniquely prepared remodelable extracellular matrix (ECM) materials retaining at least a portion of their native bioactivity. Also described are methods for forming and using such products. In one embodiment, an inventive product comprises a layer of remodelable ECM material modified through contact with periodic acid or a salt thereof. In some forms, such a modified ECM material layer includes non-native Schiff's base crosslinks within and/or between certain components of the ECM material (e.g., between two collagen molecules, two non-collagen molecules, and/or a collagen molecule and a non-collagen molecule). Other inventive products are comprised of various gels, foams, pastes, and formed, coherent, porous bodies at least containing ECM materials that have been modified in accordance with the present invention.
1. A medical graft material, comprising:
a layer of isolated remodelable extracellular matrix material that has been modified through contact with periodic acid or a salt thereof to introduce non-native Schiff base crosslinks between components of the extracellular matrix material and enhance the biostability of the extracellular matrix material; and
at least one bioactive agent native to an animal source tissue for the extracellular matrix material retained in the modified extracellular matrix material layer, the bioactive agent selected from the group consisting of a proteoglycan, a growth factor, a glycoprotein, and a glycosaminoglycan.
2. The medical graft material of claim 1 , wherein said modified extracellular matrix material layer comprises submucosa.
3. The medical graft material of claim 2 , wherein said submucosa comprises porcine submucosa.
4. The medical graft material of claim 2 , wherein said submucosa comprises small intestine submucosa, urinary bladder submucosa, or stomach submucosa.
5. The medical graft material of claim 1 , wherein said modified extracellular matrix material layer comprises serosa, pericardium, dura mater, peritoneum, or dermal collagen.
6. The medical graft material of claim 1 , comprised of a multilaminate construct in which said modified extracellular matrix material layer provides a first layer, said multilaminate construct also including at least a second isolated remodelable extracellular matrix material layer bonded to said first layer at least in part through said non-native Schiff base crosslinks.
7. The medical graft material of claim 1 , further comprising at least one additional bioactive agent added to the modified extracellular matrix material layer.
8. The medical graft material of claim 7 , wherein said at least one additional bioactive agent is non-native to the source of the extracellular matrix material layer.
9. The medical graft material of claim 7 , wherein a Schiff's base crosslink bonds said at least one additional bioactive agent to said modified extracellular matrix material.
10. The medical graft material of claim 1 , wherein said modified extracellular matrix material layer is a first material layer, and wherein said medical graft material further includes a second layer of isolated remodelable extracellular matrix material coupled or bonded to said first material layer.
11. The medical graft material of claim 10 , wherein said second extracellular matrix material layer has been modified through contact with periodic acid or a salt thereof.
12. The medical graft material of claim 10 , further comprising one to eight additional layers of extracellular matrix material, wherein said one to eight additional extracellular matrix material layers have been modified through contact with periodic acid or a salt thereof.
13. A medical graft material, comprising:
a layer of isolated remodelable extracellular matrix material that has been modified to introduce non-native Schiff base crosslinks between components of the extracellular matrix material and enhance the biostability of the extracellular matrix material; and
at least one bioactive agent native to an animal source tissue for the extracellular matrix material retained in the modified extracellular matrix material layer, the bioactive agent selected from the group consisting of a proteoglycan, a growth factor, a glycoprotein, and a glycosaminoglycan.
14. The medical graft material of claim 13 , wherein the extracellular matrix material has been treated with a reducing agent and an amine-containing compound after modification to introduce said non-native Schiff base crosslinks.
15. The medical graft material of claim 13 , wherein the extracellular matrix material comprises submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum or basement membrane.
16. The medical graft material of claim 13 , comprised of a multilaminate construct in which said modified extracellular matrix material layer provides a first layer, said multilaminate construct also including at least a second isolated remodelable extracellular matrix material layer bonded to said first layer at least in part through said non-native Schiff base crosslinks.
17. The medical graft material of claim 13 , wherein said layer of isolated remodelable extracellular matrix material that has been modified by contact with a periodate to introduce said non-native Schiff base crosslinks.
18. The medical graft material of claim 17 , wherein the extracellular matrix has been modified to introduce non-native Schiff base crosslinks between components of the extracellular matrix material and enhance the biostability of the extracellular matrix material.
19. The medical graft material of claim 17 , wherein the extracellular matrix has been modified to introduce non-native Schiff base crosslinks between components of the extracellular matrix material and enhance the anti-immunogenicity of the extracellular matrix material.
20. A medical graft material, comprising:
a layer of isolated extracellular matrix material that retains at least one of a proteoglycan, a growth factor, a glycoprotein, and a glycosaminoglycan, from an animal source tissue for the layer of isolated extracellular matrix material; and
wherein said extracellular matrix material has been modified through contact with periodic acid or a salt thereof so as to enhance the biostability of the extracellular matrix material.
21. The medical graft material of claim 20 , wherein the extracellular matrix material has been treated with an amine-containing compound after the modification through contact with the periodic acid or salt thereof.
22. The medical graft material of claim 20 , wherein the extracellular matrix material has been modified through contact with sodium periodate.
23. The medical graft material of claim 20 , wherein the extracellular matrix material comprises submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum or basement membrane.